Literature DB >> 16490286

Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.

A-M Nilselid1, Pia Davidsson, Katarina Nägga, Niels Andreasen, Pam Fredman, Kaj Blennow.   

Abstract

Clusterin is suggested to be involved in the pathogenesis of Alzheimer's disease. Clusterin expression is increased in brain tissue in affected regions of Alzheimer patients, and intense clusterin staining is found in both senile plaques and in neuronal and glia cells. In contrast, the cerebrospinal fluid level of clusterin in Alzheimer patients has, thus far, been found unchanged. Clusterin is a glycosylated protein, and an alteration of its glycosylation in Alzheimer's disease might influence accurate quantification in cerebrospinal fluid through interference of antibody binding to the protein. Using enzymatic deglycosylation of clusterin isolated from cerebrospinal fluid, we found that the carbohydrates attached to clusterin were of the N-linked type and sialic acids. Based on this finding, cerebrospinal fluid samples from Alzheimer patients (n=99) and controls (n=39) were analysed. The samples were treated with peptide: N-glycanase F, cleaving off N-linked carbohydrates, and clusterin was quantified before and after deglycosylation using a new sandwich enzyme-linked immunosorbent assay. Clusterin was significantly increased in Alzheimer patients, in both native (7.17+/-2.43 AU versus 5.73+/-2.09 AU; p=0.002), and deglycosylated samples (12.19+/-5.00 AU versus 9.68+/-4.38 AU; p=0.004). Deglycosylation led to increased measured levels of clusterin by 70% (p<0.001) in Alzheimer patients and 67% (p<0.001) in controls. These findings indicate that glycosylation of proteins may interfere with their quantification. The results show that clusterin is significantly increased in cerebrospinal fluid from Alzheimer patients as a group, supporting that clusterin might be involved in the pathogenesis of Alzheimer's disease. However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490286     DOI: 10.1016/j.neuint.2005.12.005

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  31 in total

1.  Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Authors:  N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas
Journal:  Clin Exp Immunol       Date:  2016-03-31       Impact factor: 4.330

2.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

Review 3.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

4.  8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Authors:  Leila Choe; Mark D'Ascenzo; Norman R Relkin; Darryl Pappin; Philip Ross; Brian Williamson; Steven Guertin; Patrick Pribil; Kelvin H Lee
Journal:  Proteomics       Date:  2007-10       Impact factor: 3.984

5.  Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats.

Authors:  Patricia M Gaffney; Bradd Barr; Joan D Rowe; Cyrus Bett; Ioannis Drygiannakis; Federico Giannitti; Margarita Trejo; Majid Ghassemian; Patrice Martin; Eliezer Masliah; Christina J Sigurdson
Journal:  FASEB J       Date:  2014-11-24       Impact factor: 5.191

Review 6.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

7.  Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers.

Authors:  Susanne Schöttler; Greta Becker; Svenja Winzen; Tobias Steinbach; Kristin Mohr; Katharina Landfester; Volker Mailänder; Frederik R Wurm
Journal:  Nat Nanotechnol       Date:  2016-02-15       Impact factor: 39.213

8.  Time-dependent decrease of clusterin as a potential cerebrospinal fluid biomarker for drug-resistant epilepsy.

Authors:  Weihua Yu; Dan Chen; Zhihua Wang; Chunlei Zhou; Jing Luo; Yali Xu; Lan Shen; Huan Yin; Shuxin Tao; Zheng Xiao; Fei Xiao; Yang Lü; Xuefeng Wang
Journal:  J Mol Neurosci       Date:  2014-02-02       Impact factor: 3.444

9.  Association between CLU gene rs11136000 polymorphism and Alzheimer's disease: an updated meta-analysis.

Authors:  Ruixia Zhu; Xu Liu; Zhiyi He
Journal:  Neurol Sci       Date:  2018-02-02       Impact factor: 3.307

Review 10.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.